ET-traps Overview
- Founded
-
2015

- Status
-
Private
- Employees
-
3

- Latest Deal Type
-
Accelerator/Inc
- Latest Deal Amount
-
$100K
- Investors
-
2
ET-traps General Information
Description
Operator of a research company and developer of a novel therapeutic for various diseases headquartered in Cambridge, United Kingdom. The company has developed an Fc-based fusion protein that has a very high binding affinity in the picomolar range, which is higher than ERAs that are already in clinical use, it focuses on sequestering pathologically elevated levels of Endothelin-1 in different diseases, enabling doctors to treat cardiovascular atherosclerosis, chronic kidney disease, pulmonary arterial hypertension, cancer, diabetes and neurodegenerative disorders.
Contact Information
Website
www.et-traps.co.uk
Formerly Known As
EndoTraps
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Pharmaceuticals
Primary Office
- 28 Street Stephens Place
- Cambridge CB3 0JE
- England, United Kingdom
ET-traps Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Accelerator/Incubator | $100K | 00000 | Completed | Startup | ||
1. Accelerator/Incubator | 12-Apr-2015 | Completed | Startup |
ET-traps Executive Team (4)
ET-traps Signals
ET-traps Investors (2)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Accelerate Cambridge | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
Founder.org | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |